I suppose, but it is a bit hard to relate. Why do people form such expectations about a 2a stage trial? To me, that make no sense and suggests a substantial number of investors either dont quite understand the types and phases of biotech trials and are overly reactive. Maybe anns need more contextual info to assist retail in understanding some of these fundamentals?
Ann: ACW XanaCIDD phase 2a trial topline results, page-48
-
- There are more pages in this discussion • 83 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
